Not medical advice. Tesamorelin is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Tesamorelin is listed in our catalogue under “HGH / Somatropin.” In scientific publications it is discussed in technical language; this page translates the general themes into everyday wording while staying faithful to research-only framing.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Tesamorelin, FDA-approved synthetic GHRH(1-44) analogue with N-terminal hexenoic acid modification for DPP-IV resistance and pulsatile GH release.
Peer-reviewed literature typically discusses Tesamorelin in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Growth-hormone axis peptides are researched for how they signal through the GH/IGF pathway in animals and cells. Studies focus on endocrine biology and metabolism, not on prescribing or outcomes in people.
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 1–2 mg daily subcutaneously (research vials supplied at 5 mg or 10 mg) · Once daily subcutaneous injection · Elimination t½ ≈ 8–26 min; Tmax = 0.15 h (median); absolute bioavailability <4% (SC); GH pulse duration 2–4 h post-injection; IGF-1 elevation accumulates over weeks of repeated dosing. AUC 34% higher in HIV-infected patients vs. healthy subjects.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Tesamorelin is a synthetic 44-amino-acid analogue of growth-hormone-releasing hormone (GHRH) stabilised with an N-terminal hexenoic acid. It signals the pituitary to release growth hormone and is the molecule approved (as Egrifta) to reduce excess visceral fat in HIV-associated lipodystrophy. New-U's tesamorelin is research-grade material supplied for laboratory use only — not the approved drug and not for human use.
In the research and clinical literature tesamorelin activates the pituitary GHRH receptor to raise growth hormone and IGF-1, with a notable effect on visceral (deep abdominal) adipose tissue. These are findings for the molecule; New-U supplies research-grade tesamorelin for laboratory research only and implies no human therapeutic effect.
Clinically the approved drug is used to reduce visceral fat in HIV-associated lipodystrophy. In the research literature it is a tool compound for GH-axis and adipose-tissue studies. New-U supplies research-grade tesamorelin strictly for in-vitro and animal-model research, not for human use.
The pharmaceutical tesamorelin (Egrifta) is FDA-approved for HIV-associated lipodystrophy. That approval applies to the finished prescription drug — NOT to research-grade material. New-U's tesamorelin is an unapproved research powder supplied for laboratory research only and is not a substitute for the prescription product.
As the approved drug Egrifta, tesamorelin has a human safety dataset under medical supervision. That record does not extend to research-grade material, which is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use claims.
All three are GHRH analogs, but tesamorelin is a full 44-amino-acid version with an N-terminal hexenoic acid for DPP-IV resistance. Sermorelin is the shorter 29-residue truncation with a shorter half-life, and CJC-1295 uses either tetrasubstitution (no-DAC) or covalent albumin binding (DAC) for different duration profiles. Tesamorelin has the strongest clinical dataset.
GH itself preferentially mobilises visceral adipose tissue because visceral fat is more sensitive to catecholamine and GH-driven lipolysis than subcutaneous fat. Tesamorelin generates a physiologic GH pulse that targets exactly this compartment, which is why VAT drops while SAT is largely preserved.
Like any GH-driven protocol, tesamorelin can transiently raise fasting glucose and worsen insulin sensitivity because GH opposes insulin action. Clinical trials reported modest glycemic changes that are typically manageable but warrant monitoring in research protocols.
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C, protect from light, and use within the peptide's typical stability window. Avoid shaking, which can denature the peptide.
Tesamorelin is a GHRH analogue studied for its effect on visceral fat via the body's own GH release. The published clinical literature on the reference drug reports that the visceral-fat reduction is not maintained after the peptide is discontinued — visceral adipose tissue tends to return toward baseline — because the effect depends on ongoing GH-axis stimulation rather than a permanent change. Those findings describe the approved medicine in human studies; tesamorelin here is an unapproved research-grade peptide for laboratory research only and is not for human use.
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Other compounds researchers often read about alongside Tesamorelin.
Primary literature and registries for Tesamorelin, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: TH-9507, Growth Hormone Releasing Factor 1-44 Analogue, trans-3-Hexenoic Acid GHRH, Tesamorelin Acetate